FutureNeuro partners with Ergo to develop eHealth technology for people with epilepsy
DUBLIN, Oct. 11, 2018 – FutureNeuro, the SFI Research Centre for chronic and rare neurological conditions based at RCSI (Royal College of Surgeons in Ireland), has announced its partnership with Irish Cloud solution provider Ergo to enhance crucial eHealth infrastructure in Ireland and provide improved monitoring for people living with epilepsy.
The research will provide a voice-based user interface for an existing Epilepsy Patient Portal allowing people to co-author their own electronic patient record (EPR). This enhanced user interface, that enables real-time reporting of health information using the patients’ voice, will make the system more useful for clinicians and easier to use for patients.
This project combines Ergo’s software development skills with FutureNeuro’s understanding of the needs of people with epilepsy, their families and healthcare providers. The goal of the project is to improve the Epilepsy Patient Portal functionality in order to deliver optimal patient care.
Ultimately, these eHealth advances can help patients and doctors continuously monitor patients’ symptoms via mobile devices. This eHealth technology platform also has the potential to enhance future research and clinical trials on epilepsy.
Mary Fitzsimons, collaborator at FutureNeuro and Director of the Epilepsy eHealth Lighthouse Programme at RCSI said: “Conditions like epilepsy currently rely on patient history to characterise events, which is subject to patient recall and accurate disclosure. Real-time reporting of patient seizure information and activities of daily living provides a wealth of clinical information that can inform management by analysis of data over an extended monitoring period. FutureNeuro’s industry-supported research with Ergo will result in new smart health solutions being developed and clinically evaluated.”
In 2015, the HSE and eHealthIreland designated the National Epilepsy eHealth programme as a Lighthouse for the country to help build a national understanding of the quality, safety and efficiency benefits of electronic health records and to illustrate the economic opportunity for Ireland in terms of becoming a global leader in eHealth technology development and use.
Derek Kehoe, Director at Ergo, said: “We are delighted to be part of this multidisciplinary group that looks to utilise technology to help support the care of people with epilepsy. This is another step on the path to a true patient-centric approach, allowing them to interact with technology though voice to support their long-term care. We have successfully delivered on the Lighthouse projects to date, allowing patients to interact with their records. This represents another opportunity to deliver on the potential of eHealth in Ireland.”
FutureNeuro, which is funded by Science Foundation Ireland, aims to deliver advances in understanding disease initiation and progress. With this understanding, and through industry partnerships, new technologies and solutions for the treatment, diagnosis and monitoring of chronic and rare neurological diseases will be developed.
Prof Mark Ferguson, Director General of Science Foundation Ireland and Chief Scientific Adviser to the Government of Ireland, welcomed the collaboration, saying: “The SFI Research Centres bring together the best researchers in academia and companies across Ireland to work on strategic research programmes, with the primary objective of delivering significant economic and societal impact to Ireland. I am delighted to see this collaboration come to fruition between FutureNeuro and Ergo, which has the potential to transform the lives of those living with neurological disorders using innovative eHealth technologies.”
Director of Research and Innovation at RCSI, Professor Ray Stallings, said: “The partnership between FutureNeuro and Ergo will further enable healthcare professionals to provide the best quality of care for people with epilepsy. I look forward to the success of this new technology in this study and the potential benefits it will bring to future epilepsy research.”
Epilepsy affects more than 60 million people worldwide, making it one of the most common neurological conditions. Research based on large health datasets can help researchers understand the underlying cause of the disease, provide insights into disease progression and response to treatment within a population. Those insights can then be used to assess risk factors, inform treatment planning for individuals and distribution of healthcare resources.
About FutureNeuro
FutureNeuro is a new SFI Research Centre dedicated to developing new technologies and solutions for the treatment, diagnosis, and monitoring of chronic and rare neurological diseases. It is supported by Science Foundation Ireland. Initially focusing on Epilepsy and Motor Neuron Disease, FutureNeuro will build rapidly to help transform the lives of the approximately 700,000 people affected by neurological disorders in Ireland.
It connects national and multinational industry with key academics and clinicians based in our leading hospitals to provide diagnostic, therapeutic and E-Health solutions. FutureNeuro’s projects with industry partners will bring diagnostic supports to market, a pipeline of new drugs, and connected health solutions that enable patients to monitor and report their health better than ever before.
futureneurocentre.ie
ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease
Unique discovery platform generates new antibody candidates that block
a root cause of Parkinson's Disease
TORONTO and CAMBRIDGE, MA, Oct. 11, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the identification of several potential antibody therapeutic candidates aimed at selectively targeting toxic oligomers of the protein α-synuclein, considered a root cause of Parkinson's disease (PD).
"Using our unique discovery platform, we were able to identify several novel targets displayed on toxic oligomers of α-synuclein and generate antibody candidates capable of protecting brain neurons against such toxic oligomers in vitro," stated ProMIS Executive Chairman Eugene Williams. "We now look forward to further validation and selection of the most promising candidates to move forward in development for PD. We see our emerging Parkinson's disease program as an ideal pharma partnering opportunity."
ProMIS has retained Red Sky Partners, LLC of Cambridge, Mass., to support partnering efforts for its novel antibody candidates for Parkinson's disease.
In vitro studies, performed at Neuron Experts (Marseille, France), a specialized contract research organization, investigated the neuroprotective effect of ProMIS' antibodies on rat primary dopaminergic neurons injured by exposure to toxic oligomers of α-synuclein, an in vitro model of PD. In the test, several ProMIS antibodies, selectively targeting toxic oligomers of α-synuclein, significantly blocked the death of neurons induced by these oligomers.
Commenting on these results, Dr. James Kupiec, ProMIS Chief Medical Officer stated: "I am truly impressed with the outstanding ability and efficiency of the ProMIS platform to predict novel therapeutic targets and generate highly selective therapeutic antibodies for multiple neurodegenerative diseases. Having recently joined ProMIS from my prior position as VP, Global Clinical Leader for Parkinson's Disease at Pfizer, I expect further development of these antibody candidates will offer real hope for disease-modifying therapy in PD."
Parkinson's disease is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons located in the midbrain and the presence of intraneuronal inclusions (Lewy bodies/Lewy neurites), consisting mainly of aggregates of α-synuclein that can propagate from cell to cell. Recent published data indicate 1,2,3,4 that a-synuclein toxicity resides primarily with these aggregated, oligomeric forms of the protein.
Pursuant to its expanded license agreement with the University of British Columbia, ProMIS holds exclusive, worldwide license to these novel therapeutic targets and antibodies; patent filings have been submitted to the United States Patent Office.
References: 1Fusco et al, 2017, Science; 2Choi et al, 2018, Cell Reports; 3Peelaerts et al, 2015, Nature; 4Games et al, 2014, J Neuroscience
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
About Neuron Experts
Neuron Experts is a Contract Research Organization specializing in the study of neuro-active compounds. The company uses its own tests based on primary neuronal cell cultures modeling neurodegenerative diseases and neuronal impairment-induced skin disorders.
For further information about ProMIS Neurosciences, please consult the Company's website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
Think Research Announces Technical Update Providing Easily Ingestible Clinical Content for Cerner
TORONTO, Oct. 9, 2018 /CNW/ - Think Research (the "Company"), a leading digital healthcare platform provider, today announced enhanced capabilities in delivering evidence-based clinical content to Cerner Millennium customers through Cerner PowerPlans, Care Sets, and Patient Care Plans.
For years, Think Research has brought value to various Electronic Health Record (EHR) platforms through its Entrypoint application as well as through delivery directly into Computerized Physician Order Entry (CPOE) systems.
This enhanced integration ensures that client implementations can be delivered in a streamlined manner as the Company looks to scale its offering across the hundreds of hospitals looking to fill a clinical gap in their EHR deployments.
"With over 45 Cerner clients currently using Think Research's Order Sets," says Brynne Eaton-Auva'a, VP of Business Development at Think Research, "we have had significant experience understanding what it takes from both a clinical and technical perspective to make sure our Cerner clients have the best possible clinical content at their fingertips, within their workflows."
Think Research's Order Sets are one of several clinical applications that help bring the latest in evidence-based best practice treatments to the bedside. Order Sets are designed to fit naturally into each healthcare organization's unique workflow, allowing clinicians to access information quickly and seamlessly.
Think Research's work with Cerner will extend this capability, and the resulting data insights, to a larger clinical base around the world.
About Think Research
Think Research's mission is to organize the world's health knowledge, so everyone gets the best care. The company takes the ever-growing body of clinical evidence and health care algorithms to create software applications that drive high-quality clinical decision making. Think Research's solutions are provided through a secure, multi-application platform that is used by clinicians and patients at the point of care and is deployed in over 1,100 facilities in Canada, the US and the EU, impacting millions of patients annually.
SOURCE Think Research
Powerful Call To Action Seeks To Abolish Conversion Therapy
New York, NY, October 10, 2018 — You might have thought that "conversion” therapy practices on children in America would have been outlawed years ago. You'd be wrong. This state-sanctioned practice to try to change a child's sexual orientation or gender identity is alive and well—and living in the United States.
Vellah Jones' new book, Dear Congress: Voices of American Children Currently Being Abused by Conversion Therapy, bravely pulls back the curtain on conversion therapy through the voices of 12 American children currently undergoing what amounts to little more than legalized torture. Jones, who sees a correlation between conversion therapy and child abuse, provides examples of the occurrence of neglect, as well as physical, psychological, sexual and emotional abuse during conversion therapy sessions by mental health professionals.
"These 12 high school children represent tens of thousands of children across the country,” Jones said. "This is a practice that's been proven to have no success in changing a person's sexual orientation or gender identity and is known to impair a child's development and result in increased juvenile homelessness, addiction and suicide.
As Jones' first public effort to shine a light on the horrors of conversion therapy and to effect positive legislative change, Dear Congress is a call to action for everyone to press for an end to conversion therapy practices on juveniles.
For more information, please go to: www.dearcongress.love.
Dear Congress: Voices of American Children Currently Being Abused by Conversion Therapy
Release date: August 23, 2018
Published in the USA by Legacy Projects
ISBN–13: 978-1725081345
ISBN–10: 1725081342
TIP SHEET
###
Reviews of Dear Congress:
Bruce Kluger, columnist, USA Today: "Conversion therapy is the waterboarding of impressionable young minds, a sanctioned modern-day torture so ignorant of science and abuse in practice that in 2018 it continues to waste the lives of millions around the world, nearly 700,000 in America alone. With their landmark book, Vellah Jones and her 'Children's Committee' have done more than simply expose the politics and perversion ... (they) also reveal, bit by painful bit, the human toll suffered by its innocent victims, while simultaneously providing them a potent forum—and steely solidarity—to fight back and abolish this psychological brutality.”
Kathryn Smerling, PhD, licensed family therapist, New York City: "I wish this book did not exist, that state and federal law prohibited the horrible psychological, physical and emotional abuse of conversion therapy. Hopefully, this book will help to end these practices, and for all.”
| Green Relief Inc. The Leading Licensed Producer in Canada to use Aquaponics Technology to Grow Cannabis
-Donating fish used in their aquaponic systems to shelters across the GTA- |
|
| HAMILTON, ON, October 10, 2018 - Green Relief Inc., a licensed producer of medical cannabis in Flamborough, Ontario, has become the world’s leading expert on growing cannabis on a commercial scale using aquaponics. Aquaponics is a sustainable form of agriculture where fish and plants are grown together in a natural ecosystem-based environment. Aquaponics combines the best attributes of aquaculture and hydroponics without the use of chemical additives or having to discard harmful water into the environment. It can produce more than ten times the crop yield per acre and uses 90% less water than conventional farming. |
|
| With the natural resources of our planet being depleted at an alarming rate, Green Relief believes in striving to embed sustainability in every fiber of its company through awareness, involvement, and innovation. They incorporate strong environmental, health, and social values in everything they do from the geothermal advantage of their earth-sheltered building to the 100% use of energy-saving LED lights and environmentally responsible aquaponic growing systems. From their planned integration of job positions for the physically disabled through the Ontario Disability Employment Network to donating organically fed tilapia to the local homeless shelters for people in need.
Green Relief’s team of exceptional horticulturalists, scientists, and aquaponic specialists are committed to and actively engaged in the company’s mandate for sustainability. It’s this greater purpose that has created such a powerful company culture where all the employees are personally engaged in a process where they can actually see how they are improving peoples’ lives and making a difference in the world. Exceptional people growing an exceptional plant.
At Green Relief, the cannabis plants are propagated from carefully selected mother plants that are replaced regularly to ensure that the strong genetics of each strain is maintained for optimum cannabinoid and terpene production. This ensures that medical cannabis is consistent from batch to batch resulting in a dependable and high-quality product. Carefully tracked batches of each plant strain are harvested every two weeks to ensure maximum freshness, quality, and traceability is maintained for their patients.
The highly qualified Quality Assurance team at Green Relief ensures that all procedures and protocols are strictly applied during the growing, harvesting, drying, and extracting processes for their medical cannabis. All their products undergo strict testing by both their in-house scientists and third-party laboratories. Products are tested for potency levels as well as for microbiological contaminants, heavy metals, pesticides, and aflatoxins to ensure that patients are receiving a safe and consistent product in every order. |
|
| Warren Bravo is the co-founder and CEO of Green Relief Inc., a licensed producer devoted to bringing innovation and social responsibility to the medical cannabis industry through the use of aquaponics. In the early 1980’s, Warren became the third-generation of the Bravo family to join the family business, Bravo Cement Contracting. By the early 1990’s, Warren had climbed the ladder to company president, leading the firm to become one of the most significant concrete companies in Canada with a worldwide presence. In 2013, Warren took a leap of faith leaving Bravo Cement to establish Green Relief Inc. with co-founder Steve LeBlanc. Their mission: help patients improve their quality of life while furthering the science of medical cannabis and sustainable agriculture around the world.
Recently, Green Relief has expanded its operations by acquiring a 100,000 sq.ft. Facility in nearby Stoney Creek, Ontario, providing a real boost to the local economy. The facility, which will contain 75,000 sq. ft. of growing area and 25,000 sq. ft. of office space, allows Green Relief to grow its medicinal products on a much larger scale. The building will act as an extension of the company’s headquarters in Flamborough and includes plans for installing a second floor, which will double the production output. Green Relief will be hosting a job fair in the coming months and is very excited to be expanding employment opportunities in the Stoney Creek area by creating approximately 100 new living wage jobs. Green Relief also plans to go public giving an initial public offering (IPO) in the coming months. |
|
| -30-
About Green Relief Inc. Green Relief Inc. is a licensed Canadian producer of medical cannabis under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) and are fully licensed to produce and sell both dry cannabis products and cannabis oils. Their mission: To help patients improve their quality of life, invest in furthering the science of medical cannabis through meaningful research, and advance sustainable agriculture around the world through aquaponics.
www.greenrelief.ca |
|
Mephisto Originals launches, "Mephisto Walks" - Celebrating 50 years with its Updated Classic
With an LA Pop-Up Experience / Store and Campaign
#WhoWalksInLa
International footwear brand Mephisto celebrates 50 years making the ultimate comfort / fashion shoe with the re-introduction of its Mephisto Originals collection.
Addressing the age-old question "Who walks in LA?" with the two-word tagline of its new campaign: ‘Mephisto Walks’.
The tagline alludes not only to the craftsmanship that accounts for the Mephisto walking experience, but also to the attitude and style of Mephisto Originals.
Photographers, Phil Knott and Gaell Beller, along with Parkour artist-turned filmmaker, Oleg Cricket, have created content offering their interpretations of the notion that, "No Matter how you get there....Mephisto Walks"
The campaign celebration officially launches with a VIP event on, Thursday, October 11th at Sportie LA's infamous Influencer car-park on Melrose Ave, this is followed by a 4-day only pop-up store, located at: 7763 Melrose Ave. LA 90046.
Gripping Memoir Details Life Before And After Debilitating Stroke
Trevose, PA, October 9, 2018 ― For Mary Reid-Hill, the word "no” means surrender. It means life on the couch. It means dying a slow death. So never tell Mary that she can't do something. Because she'll do everything in her power to prove you wrong.
Mary entered "adulthood” with a load of problems to unpack, including a twisted, abusive childhood; a misguided teen marriage; and a cancer diagnosis at the tender age of 22. Somehow, in spite of it all, she used her skills as a visual artist to carve out a career in the male-dominated world of sign design and installation.
But life wasn't done testing her. At age 38, at the peak of her success, she suffered a major stroke which left her with essentially half her brain and body capacity. For more than 15 years, she has defied doctors, therapists, and even friends and family to stubbornly and relentlessly find her own equilibrium and happiness, "in spite of” all of her health challenges, psychological roadblocks and spiritual upheaval.
But that's just Mary.
And now, she's sharing her remarkable story in her inspirational memoir, In Spite Of . . . How I Survived Abuse, Cancer, and a Giant F@#%ing Stroke, as told to David Tabatsky—author, co-author and/or editor of more than thirty books, covering a vast range of subjects. For more information on David, please visit his website at: www.tabatsky.com.
Mary's approach is refreshingly candid and infused with humor as she chronicles a series of life events that would emotionally cripple most people, including her messed- up childhood, two bad marriages, the devastating stroke, her battles with weight and insurance companies, and the death of her husband. Through it all, her no-nonsense prose underscores why she's become a living example of what the human spirit is ultimately all about and how, in spite of it all, she's still here.
Mary was born and raised in Bucks County, Pennsylvania, and still lives there today, on the corner of Hope and Humor. For the past 17 years, Mary has been unable to hold down a job, due to a disability stemming from her stroke. However, she remains as active as possible, renovating her home, refinishing furniture and continuing her main passion––drawing. Her memoir includes 15 original drawings, some of which she created before the stroke, and several after, when she had to teach herself to draw all over again, this time with her left hand. On top of that, Mary cares for two dogs and occasionally her two closest sisters.
For more information, please visit the website at: www.inspiteof.life.
In Spite Of . . . How I Survived Abuse, Cancer, and a Giant F@#%ing Stroke
Legacy Projects
Release Date: August 2018
ISBN–13: 978-1722983352
ISBN–10: 1722983353
Collaboration Between National Physical Laboratory and Mediso
AnyScan (SPECT/CT/PET) triple modality system
BUDAPEST, Hungary, Oct. 10, 2018 /CNW/ - Breakthrough scientific collaboration between National Physical Laboratory (NPL) and Mediso Medical Imaging Systems Ltd. has begun in the United Kingdom after installation of a newly procured triple modality AnyScan (SPECT/CT/PET) system.
(Logo: https://mma.prnewswire.com/media/751864/Mediso_Logo.jpg )
The new triple modality system provides the benefit of much higher sensitivity and resolution compared to conventional SPECT imaging. The excellent SPECT image quality is a direct result of the novel three-headed SPECT detector technology and the applied multi-pinhole collimation. Enabling image quality levels that are comparable with those normally seen in PET. This unique multimodality imaging system enables SPECT, CT and PET studies to be performed in one room. A feature that will benefit a number of customers and their patients.
"The AnyScan system will deliver major new capabilities at NPL as part of our new Metrology for Medical Physics Centre (MEMPHYS), supporting rapid acceleration for the development and implementation of innovative early diagnostic and therapeutic technologies, for conditions such as cancer, dementia and heart disease into clinical practice," said Dr. Andrew Robinson, Head of Nuclear Medicine Metrology, National Physical Laboratory, Teddington, Middlesex UK.
"It had great significance to equip NPL with our state-of-the-art appliance," said István Bagaméry, Managing Director of Mediso Ltd. "AnyScan is our flagship equipment which brings nuclear and molecular imaging expectations to the limits. During our collaboration we will incorporate the findings to our imaging products. It is crucial for us to utilise the results from the NPL project and make them accessible for other users as well."
The AnyScan camera will allow NPL to develop unique measurement capabilities and deliver the first SPECT/CT/PET scanner in the world directly calibrated against primary standards of radioactivity, providing clinicians and pharmaceutical developers with confidence in their medical image decision-making and progress of clinical drug trials.
Mediso introduction
Mediso Ltd. works in the field of nuclear and molecular imaging focusing on development, manufacturing, sales and servicing of multi-modality in-vivo imaging systems. The AnyScan® family is the first triple modality choice for clinical imaging. The system was sold, installed and supported by Bartec Technologies Ltd. Mediso's exclusive representative in UK and Ireland.
NPL introduction
The National Physical Laboratory (NPL) is the UK's National Measurement Institute, and is a world-leading centre of excellence in developing and applying the most accurate measurement standards, science and technology available.
SOURCE Mediso Medical Imaging Systems
Christiana Care Launches #HitMeWithYourFluShot Campaign to Protect Employees During Flu Season
| Health System Aspires to Vaccinate all 11,000 Employees on Oct. 11th
WHAT: Christiana Care Health System will launch one of the largest flu vaccination campaigns in history Thursday, Oct. 11, when the health system attempts to vaccinate all 11,000 of its employees in one day.
During its special #HitMeWithYourFluShot campaign, Christiana Care employees will be able to receive their flu shot on site at both Christiana Hospital in Newark and Wilmington Hospital in Wilmington, Del. Employees will have the opportunity to get vaccinated in all 70+ Christiana Care practices and sites located Maryland, Pennsylvania, New Jersey and all three counties in Delaware.
WHY: Flu vaccination has important benefits. It can reduce flu illnesses, doctors’ visits, and missed work and school, as well as prevent flu-related hospitalizations. Just last month, the U.S. Centers for Disease Control and Prevention announced that 80,000 people died from the flu last year. It was the worst flu season in the United States since 1976. In recent years, the number of flu-related deaths averaged between 12,000 and 56,000.
WHEN: Thursday, Oct. 11th from 4 a.m. to 9 p.m.
FUN EVENTS:
Christiana Hospital
- 11 a.m. to 1 p.m. – WJBR-FM broadcasting live, J. Bear mascot, photo booth for employees to get their picture taken after they get vaccinated.
Wilmington Hospital
- 9:30 a.m. to 10:30 a.m. –Wilmington Blue Rocks Mascot Rocky Bluewinkle.
- 9 a.m. to 11 a.m. – PAWS for People therapy dogs to visit with employees while they wait in line to get their flu shot.
|
Gone in 60 Seconds…
Bratoxinsta® Wrinkle Serum Delivers Immediate Results with High Concentration of Key Ingredients from the Amazon.
When it comes to banishing wrinkles and crow’s feet, an immediate result is where it’s at. Gone are the days of waiting 8 to 12 weeks for improvement. People want noticeable wrinkle fading within minutes. They want to feel it working and look in the mirror as the change is happening. Brazilian Skin’s line of creams and serums delivers exactly that. It combines science and ingredients from the Amazon rainforest to deliver dermatologist-approved topical age reversal with effects similar to Botulinum Toxin, aka…Botox.® Wrinkles are gone within minutes without needles. Brazilian Skin offers a type Botox result without the appointments, expense and needles. Dr. Vishal Kapoor, a Beverly Hills, CA Board Certified Plastic Surgeon and Medical Advisor to Brazilian Skin explains how this skincare line really delivers results quickly.
Bratoxinsta® The 60 Second Smoother of Lines and Wrinkles
Within 60 seconds of application, the state-of-the-art minerals and antioxidants found in this serum gets to work fast to plump up skin, tighten and smooth out wrinkles. With clinically dosed concentrations of purified and refined clay, Peptides, Euterpe Oleracea (Acai) Fruit Extract, Perilla Frutescens (Chinese Extract), Acai Palm Tree Extract, Chinese Basil Plant’s Rosmarinic Acid, known for its ability to plump up tired skin; Bratoxinsta offers the immediate gratification that the countless other creams and serums are missing.
“Women are always telling me that they spend money on creams and serums that do nothing. They play the waiting game and get frustrated as they throw away another cream or serum. With Bratoxinsta, there’s no waiting. You’re getting the highest amounts of these key ingredients possible and when working in concert with one another results are instantaneous,” explains Dr. Kapoor.
The powerful combination of stem-cell, antioxidants from Açai and peptides help to improve long-term appearance of wrinkles and will address sun damage and other issues with skin texture and tone. Some of Bratoxinsta’s ingredients will help to tighten the skin on the surface, helping to smooth fine expression lines and blur the appearance of wrinkles. Once applied, the powerful active ingredients will start working on getting your skin smoother, tighter, and more youthful-looking with every use.
Simply dispense a small amount on your fingertip and gently feather it over any wrinkles and expressions lines. Apply to a clean face, allow 60 seconds for effects to begin before applying makeup. “A little goes a very long way with Bratoxinsta. One or two drops on the fingertip will do it. You can actually watch it working in the mirror. This is what sets it aside from other creams touting themselves as ‘Botox in a Bottle,’” says Dr. Kapoor.
Main Ingredients… A Deeper Look
Magnesium Aluminum is a naturally occurring mineral created purified and refined clay, that tightens and smooths the appearance of under-eye puffiness, sagging, and fine lines.
Peptide Complex
Peptide Complex works to smooth away the look of wrinkles and expression marks.
Stem Cell Complex (Euterpe Oleracea (Acai) Fruit Extract, Perilla Frutescens (Chinese Extract). Native to the Amazon Rainforest, the Acai Palm Tree is renowned its ability to thrive in harsh conditions. The Chinese Basil Plant is rich in Rosmarinic Acid, which is known for its ability to plump up tired skin. These 3 antioxidants help to defend against oxidative stress by effectively disarming radicals.
“Stem cells slow down aging by defending skin against stress and serving as an internal repair system. Stem cells divide without limit allowing them to replenish other cells or migrate to damaged areas to repair tissue,” explains Dr. Kapoor.
Chondrus Crispus (Seaweed) Extract Also known as Irish Sea Moss, Chondrus Crispus contains a hydrating, nutrient-rich blend of vitamins and trace minerals such as sulfur, iodine, magnesium, and selenium.
The Bratoxinsta formula also contains stem cells from the Acai Palm Tree, Basil Plant, and White Oak Plant. In addition, 6 bioactive peptides help smooth the appearance of existing fine lines and wrinkles by supporting the proteins that weaken with age. These active ingredients work synergistically with the peptides to deliver vital phytonutrients and antioxidants.
What is the recommended age group for Bratoxinsta?
Bratoxinsta is suitable for all age groups. For more mature skin, its innovative formula can help reduce the existing signs of visible aging immediately, while for younger skin, it can help prevent and delay the onset of fine lines and wrinkles. “Women will see significant and rapid improvement to fine lines, wrinkles and sagging. A woman in her 20’s and 30’s will be able to take a preventative approach to their skin care by maintaining tautness and wrinkle free texture longer,” says Dr. Kapoor.
About Dr. Vishal Kapoor, Board Certified Plastic Surgeon, Medical Advisor to Brazilian Skin
Dr. Vishal Kapoor is a Southern California native who received his medical degree from Tufts University School of Medicine in Boston, where he graduated with the highest honor, Alpha Omega Alpha, putting him in the top 10% of his class. He then went on to complete a rigorous six-year residency in the prestigious combined General and Plastic Surgery Program at The University of Washington in Seattle, one of the nation’s finest programs in Plastic Surgery. Given his desire to further hone his skills in Aesthetic Plastic Surgery, Dr. Kapoor opted to pursue additional training. His practice is based in Beverly Hills, California
